Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

3(75.0%)

Phase 3

1(25.0%)

4Total

N/A(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04367402Unknown

COST (COvid STudio) ACTION: Study for the Evaluation of Specific Antibodies Anti Covid-19 Linked to Covid-19 Infection, Symptoms and Genetic Expression of ACE2 Polymorphisms in Patients (COST ACTION)

Role: lead

NCT04155554Phase 3Unknown

Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen

Role: collaborator

NCT03685396Not ApplicableCompleted

Patient Morbidity After Palatal Free Gingival Grafts With or Without PRF Membranes Coverage

Role: lead

NCT03920787Not ApplicableUnknown

Evaluating the Effect of Inositol Supplementation in Overweight Children on Basal Insulin and Body Weight

Role: collaborator

NCT03601767Unknown

Derivation and Validation of a Prognostic Model for Septic Patients at Hospital Admission

Role: lead

NCT02232451Not ApplicableCompleted

Comparison of Loop-tip Cook Medical® Wire Versus Traditional Endoscopic Technique

Role: lead

All 6 trials loaded